Investigational drug · Phase 2
GT719
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hematological Malignancy (Leukemia- Lymphoma).
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "GT719"
First trial start
2025
Apr 18, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GT719", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hematological Malignancy (Leukemia- Lymphoma)
Approved drugs for the same conditions: Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "GT719" as an intervention, largest first.
- GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell MalignanciesRecruiting
Grit BiotechnologyIndustry
NCT06948981 · 46 participants (planned) · Start Apr 18, 2025 · Primary completion Apr 17, 2028
Drug: GT719 Injection · For: Hematological Malignancy (Leukemia- Lymphoma)
Sites: Tianjin, China
Grit BiotechnologyIndustry
NCT07131254 · 34 participants (planned) · Start Mar 10, 2025 · Primary completion Dec 1, 2027
Drug: GT719 Injection · For: Hematological Malignancy (Leukemia- Lymphoma)
Sites: Ganzhou, China
Grit BiotechnologyIndustry
NCT07132112 · 30 participants (planned) · Start Oct 28, 2025 · Primary completion Aug 2028
Drug: GT719 Injection · For: Auto Immune Disease
Sites: Nantong, China
Grit BiotechnologyIndustry
NCT07021209 · 30 participants (planned) · Start Jan 14, 2025 · Primary completion Jan 13, 2028
Drug: GT719 Injection · For: Neurological Autoimmune Diseases
Sites: Wuhan, China
- A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney DiseasesNot yet recruiting
Grit BiotechnologyIndustry
NCT07389499 · 30 participants (planned) · Start Aug 2027 · Primary completion Jun 30, 2028
Drug: CD19-targeted iNKT Cell Injection · For: IgA Nephropathy (IgAN); Membranous Nephropathy; ANCA-associated Vasculitis (AAV)/ANCA-associated Glomerulonephritis (AAGN) and 2 more
Sites: Shanghai, China
Grit BiotechnologyIndustry
NCT07122076 · 10 participants (planned) · Start Aug 22, 2025 · Primary completion Aug 21, 2028
Drug: GT719 Injection · For: Autoimmune Diseases
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.